Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.
- DOI
- 10.1038/s41467-026-69708-2
- Published
- 2026 Mar 25
- Container
- Nature communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-026-69708-2,
title = {Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.},
author = {Gounder M and Schöffski P and Jones RL and Stacchiotti S and Demetri GD and Cote GM and Agulnik M and Chugh R and Jahan T and Gupta AA and Chen TW and Ratan R and Dileo P and Drilon A and Malouf GG and Szanto A and Gupta N and Tannir NM},
year = {2026},
journal = {Nature communications},
doi = {10.1038/s41467-026-69708-2},
url = {https://doi.org/10.1038/s41467-026-69708-2}
}RIS
TY - JOUR TI - Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study. AU - Gounder M AU - Schöffski P AU - Jones RL AU - Stacchiotti S AU - Demetri GD AU - Cote GM AU - Agulnik M AU - Chugh R AU - Jahan T AU - Gupta AA AU - Chen TW AU - Ratan R AU - Dileo P AU - Drilon A AU - Malouf GG AU - Szanto A AU - Gupta N AU - Tannir NM PY - 2026 JO - Nature communications DO - 10.1038/s41467-026-69708-2 UR - https://doi.org/10.1038/s41467-026-69708-2 ER -
APA
M, G., P, S., RL, J., S, S., GD, D., GM, C., M, A., R, C., T, J., AA, G., TW, C., R, R., P, D., A, D., GG, M., A, S., N, G., & NM, T. (2026). Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.. Nature communications. https://doi.org/10.1038/s41467-026-69708-2
Source records
- pubmed · retrieved 2026-09-25T15:18:01.638Z